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Cancer  care  is big  business  and  there  are  signiﬁcant  opportunities  for unethical  marketing  practices  by
various  segments  of  the  industry.  Because  the target  population  is especially  vulnerable,  it is essential  that
strict  ethical  guidelines  are  adopted  and  that  appropriate  oversight  be  put  in place  to ensure  compliance.
The  primary  stakeholders  for  marketing  are pharmaceutical  companies  and  large  medical  centers  striving
for increased  market  share.  The  target  populations  for  marketing  of cancer  include  practitioners  as  wellancer
ulnerable populations
arketing
thics
as  consumers.  The  latter  group  is  especially  vulnerable  because  of  fears  and  anxiety  related  to  their
diagnosis.  Recommendations  for  cancer  marketing  include:  (1)  ensuring  fair and  balanced  promotion  of
cancer  services,  (2)  avoiding  exaggeration  of  claims  in the  context  of reputational  marketing,  (3)  providing
data and  statistics  to back  up  direct  and  implied  assertions  whenever  possible  and  (4)  deﬁning  eligible
patient  groups  in  the  context  of marketing  for research.
©  2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-NDCancer care in the United States is big business. In 2009, the
ational Institutes of Health estimated that the total cost of can-
er was $216.6 billion with direct expenditures for cancer-related
ealth care totaling $86.6 billion [1]. It is not surprising, therefore,
hat a substantial amount is invested into marketing for cancer ser-
ices and products each year. The stakeholders can be divided into
romotional entities and entities at whom marketing is directed.
he largest, and ﬁnancially most invested component in the former
roup is the pharmaceutical manufacturers, with additional mar-
eting conducted by hospitals and by individual physicians or
hysician group practices. Largely, the target of cancer-related mar-
eting is the consumer; this direct-to-consumer advertising can be
eﬁned as unsolicited promotion by an entity to provide informa-
ion about medicines or medical services in the popular media [2].
he other targets of marketing are providers, making this group
nique in that they both receive and convey marketing information.
thical issues
Cancer patients, and individuals who are concerned about the
evelopment of cancer, are particularly vulnerable because the dis-
ase is so feared [3]. While it is not currently considered immoral to
arket to vulnerable populations, as some have previously claimed
4], these individuals may  be at greater risk of harm to intrinsically
mmoral marketing approaches [5]. Care must be taken to abide by
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the tenants of ethical marketing put forth by the American Mar-
keting Association [6] and ensure that honesty, fairness, respect,
transparency and citizenship are core principles of any cancer mar-
keting campaign.
Pharmaceutical marketing for cancer-related products is regu-
lated by the FDA and credible evidence for any claims represented is
required. However, neither the FDA nor the FTC regulate advertise-
ments distributed by not-for-proﬁt entities such as hospitals and
medical centers. Cancer marketing by hospitals and cancer cen-
ters focus on “emotion more than fact” [7] and may  be misleading,
implying that new equipment or new services will lead to improved
outcomes without providing data to substantiate such assertions.
The recent publication by Vater et al. [8] highlights that cancer cen-
ters in particular infrequently provide information about risks and
costs but rather focus on emotional messages that utilize hope and
fear as primary motivators.
Approaches to cancer marketing
The purpose of direct-to-consumer advertising by pharmaceu-
tical companies is to sell more product, not to broadly educate the
population [3]. Studies have suggested, however, that such adver-
tising may  inﬂuence prescribing behavior as patients question their
providers about medications they have been exposed to through
the media [9]. It is felt that intense marketing of erythropoietin
stimulating agents (Procrit®, Aranesp®) to consumers, following
approval by FDA for their use in chemotherapy-associated anemia
in 1993, led in part to the dramatic increase in utilization of these
agents.
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The goals of marketing cancer services by hospitals and cancer
enters are to ultimately increase market share. Such ads are very
revalent. Woloshin et al. found that academic medical centers
ssue about 50 press releases annually, often promoting research
hat has uncertain relevance to human health [10]. This market-
ng is often reputational in nature, directed at current but also
uture patients [7]. Reputation is a powerful marketing asset and
ay drive patients to a speciﬁc location for care. Advertisements
re often structured as patient testimonials, or involve description
f new and unique equipment or services with little speciﬁc data
bout outcomes [3].
dvantages of cancer marketing for the consumer
Marketing by pharmaceutical companies and medical centers
an be beneﬁcial. It may  provide information to consumers and
o practitioners that improves patient care. Direct-to-consumer
dvertisements can prompt patients to engage in communication
ith their cancer provider about new medicines or new approaches
or their disease. In addition, consumers may  be alerted to signs and
ymptoms of cancer and seek medical evaluation.
isadvantages of cancer marketing
Marketing, especially by medical centers, is often not data
riven and may  intentionally avoid mention of outcomes and direct
elevance to contemporary cancer care. Testimonials may  be mis-
eading or misinterpreted and patients may  assume that excellent
utcomes achieved by the patient giving the testimonial represents
he average, or usual outcome for all patients. When describing
esearch, advertisements rarely mention that most patients may
ot be eligible for clinical trials or that the trials are focused on a
arrow subset of the cancer population [7]. Finally, cost is rarely
entioned in advertisements – increases in both societal costs for
ew technologies and individual costs, if patients’ insurance does
ot cover non-standard treatment approaches, may  result from
ncreased utilization [8]. All of these disadvantages are ampliﬁed
y the fact that cancer patients represent an extremely vulnerable
ector of the population.
ecommendations
Since the component of health care expenditures attributable
o cancer is great, it is reasonable to expect that pharmaceutical
ompanies, medical centers and practices will desire to advertise
heir services in order to increase market share. Given the unique
ulnerability of the population targeted, however, it is essential
hat such marketing activities do not take advantage of a cancer
atient’s fears and underlying anxiety. Recommendations for mar-
eting cancer include:
. Achieve a fair balance and ensure satisfaction of AMA  ethical
principles.. Reputational marketing is acceptable but exaggerated claims
should be avoided.
. Provide data and statistics about new technologies and
approaches or be transparent if such data does not exist.
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4. When promoting research, include information about what seg-
ment of the potential patient population may  be eligible or may
beneﬁt.
The main obstacle to fair and balanced marketing is the enormous
health care dollars spent on cancer care in the United States each
year. Marketing by pharmaceutical companies is regulated but the
FDA should have heightened scrutiny for cancer-related advertis-
ing. Hospitals are not currently regulated. However, oversight of
marketing activities could be performed by the main accrediting
agency for hospitals, the Joint Commission. If new guidelines were
put in place it is extremely likely that marketing practices would
be quickly modiﬁed to satisfy Joint Commission guidelines since
accreditation is so critical to individual hospitals. Private practi-
tioner marketing is generally on a smaller scale, and hence may  not
have the impact of other cancer-related marketing activities. Regu-
lation of private practice advertising would fall to the state boards
of registration in medicine. It is not likely that these boards would
willingly assume this responsibility.
Summary
Cancer care is big business and there are signiﬁcant opportuni-
ties for unethical marketing practices by various segments of the
industry. Because the target population is especially vulnerable,
it is essential that strict ethical guidelines are adopted and that
appropriate oversight be put in place to ensure compliance.
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